Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy-Reference-Cited by-同舟云学术

Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy

Published:2022-01 Issue:1 Volume:28 Page:19.e1-19.e7
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Pasternak Amy L.^ORCID,Marcath Lauren A.^ORCID,Li Yajing,Nguyen Vy,Gersch Christina L.,Rae James M.^ORCID,Frame David,Scappaticci Gianni,Kidwell Kelley M.^ORCID,Hertz Daniel L.^ORCID

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference31 articles.

1. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing;Birdwell;Clin Pharmacol Ther,2015

2. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation;Przepiorka;Bone Marrow Transplant,1999

3. CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration;Pasternak;Pharmacogenomics,2018

4. Effect of CYP3A4, CYP3A5, and ABCB1 polymorphisms on intravenous tacrolimus exposure and adverse events in adult allogeneic stem cell transplant patients;Hamadeh;Biol Blood Marrow Transplant,2019

5. Influence of germline genetics on tacrolimus pharmacokinetics and pharmacodynamics in allogeneic hematopoietic stem cell transplant patients;Zhu;Int J Mol Sci,2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Guidance on Selecting Optimal Steady-State Tacrolimus Concentrations for Continuous IV Perfusion: Insights from Physiologically Based Pharmacokinetic Modeling;Pharmaceuticals;2024-08-08

2. CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation;Frontiers in Pharmacology;2024-01-08

3. Association between CYP3A4 , CYP3A5 and ABCB1 Genotype and Tacrolimus Treatment Outcomes Among Allogeneic HSCT Patients;Pharmacogenomics;2024-01

4. Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients – A review;Biomedicine & Pharmacotherapy;2023-10

5. Pharmacogenomics in allogeneic hematopoietic stem cell transplantation: Implications on supportive therapies and conditioning regimens;Best Practice & Research Clinical Haematology;2023-06